<DOC>
	<DOCNO>NCT02628899</DOCNO>
	<brief_summary>To assess safety feasibility Transcatheter Aortic Valve Replacement ( TAVR ) commercially available bioprostheses elderly patient severe , symptomatic aortic stenosis ( AS ) low‐risk ( STS score ≤3 % ) surgical aortic valve replacement ( SAVR ) .</brief_summary>
	<brief_title>Feasibility Transcatheter Aortic Valve Replacement Low-Risk Patients With Symptomatic , Severe Aortic Stenosis</brief_title>
	<detailed_description>Trial Objectives : To assess safety feasibility Transcatheter Aortic Valve Replacement ( TAVR ) commercially available bioprostheses elderly patient severe , symptomatic aortic stenosis ( AS ) low‐risk ( STS score ≤3 % ) surgical aortic valve replacement ( SAVR ) . Methodology : This multicenter , prospective trial TAVR low-risk patient twelve site United States . The trial three arm . The first comprise 200 patient undergoing transfemoral TAVR . The second arm comprise200 closely matched historical control underwent isolated bioprosthetic SAVR . Historical control select among patient site undergone isolated bioprosthetic SAVR within previous 36 month . TAVR patient match SAVR patient use STS database variable perform propensity matching , include ( limited ) age , gender , race , ethnicity , STS score , valve prosthesis size . Once historical match control identify , detailed chart review abstract in-hospital 30-day outcome SAVR cohort . The third arm trial comprise registry TAVR 100 low-risk patient bicuspid aortic valve . The result registry arm analyze independently . Primary Efficacy Endpoint : All-cause mortality 30 day follow transfemoral TAVR vs. bioprosthetic SAVR . Primary Safety Endpoint : Defined composite major adverse event 30 day : a. all-cause mortality c. spontaneous myocardial infarction ( MI ) d. reintervention : define cardiac surgery percutaneous reintervention repair , alters , replaces previously implant aortic valve e. VARC life-threatening bleed f. Increase serum creatinine ≥300 % ( &gt; 3x increase compare baseline ) OR serum creatinine ≥4.0 mg/dL acute increase ≥0.5 mg/dL OR new requirement dialysis g. coronary artery obstruction require percutaneous surgical intervention h. VARC major vascular complication i. cardiac tamponade j. cardiac perforation k. pericarditis l. mediastinitis m. hemolysis n. infective endocarditis o. moderate severe aortic insufficiency p. significant aortic stenosis q. permanent pacemaker implantation r. new-onset atrial fibrillation Secondary Endpoints ( TAVR Cohort ) : 1 . Major adverse cardiovascular cerebrovascular event ( MACCE ) 30 day , 6 month , 12 month , 2 , 3 , 4 5 year , define composite : 1. all-cause mortality 2. stroke 3. spontaneous MI 4. reintervention 2 . The occurrence individual component MACCE 30 day , 6 month , 12 month , 2 , 3 , 4 , 5 year ( include stoke ) . 3 . The composite major adverse device event post-procedure , 6 month , 1 year , 2 , 3 , 4 , 5 year 4 . VARC major vascular complication , 30 day 1 year 5 . VARC life-threatening disable bleeding , 30 day 1 year 6 . Technical success upon exit operating room catheterization laboratory , define follow : 1. alive 2. successful access , delivery , retrieval device and/or delivery system 3. correct position successful deployment valve 4. need unplanned emergency surgery reintervention relate device access procedure , include reinstitution cardiopulmonary bypass post-weaning SAVR patient 7 . Device success 30 day 1 year , define follow : 1. absence procedural mortality 2. correct position single prosthetic heart valve proper anatomical location 3. device perform intend : 1 . No migration , erosion , embolization , detachment , fracture , hemolysis require transfusion , thrombosis , endocarditis 2 . Intended performance heart valve : prosthesis-patient mismatch , mean aortic valve gradient &lt; 20 mm Hg OR peak velocity &lt; 3 m/s , AND moderate severe bioprosthetic valve regurgitation 8 . Procedural success 30 day , defined device success AND major adverse device event 9 . Bioprosthetic valve regurgitation , define either moderate severe aortic regurgitation OR moderate severe paravalvular leak , hospital discharge , 12 month , 2 , 3 , 4 , 5 year 10 . Incidence new-onset atrial fibrillation hospital discharge , 30 day , 12 month , 2 , 3 , 4 , 5 year . 11 . Conduction disturbance require permanent pacemaker implantation hospital discharge , 12 month , 2 , 3 , 4 , 5 year . 12 . Change NYHA class baseline 30 day , baseline 6 month , baseline 12 month , baseline 2-5 year . 13 . Change distance walk 6-minute walk test baseline 12 month . 14 . Change responses short form Kansas City Cardiomyopathy Questionnaire ( KCCQ-12 ) baseline 12 month . 15 . Echocardiographic assessment bioprosthetic valve post-procedure , 12 month , year 2-5 , include ( limited ) : a. aortic valve mean gradient , maximum gradient , peak velocity b. calculate aortic valve area c. degree bioprosthetic valve regurgitation 16 . Assessment subclinical leaflet thrombosis multislice compute tomography , transesophageal echocardiography GFR &lt; 50 mL/min/m2 , 1 2 month . 17 . Individual patient level Success follow device success : 1 . No re-hospitalizations re-interventions underlying condition ( e.g. , HF ) 2 . Return prior living arrangement ( equivalent ) 3 . Improvement vs. baseline symptom ( NYHA Class decrease ≥ 1 ) 4 . Improvement vs. baseline functional status ( 6MWT increase ≥ 50 meter ) 5 . Improvement vs. baseline QoL ( KCCQ increase ≥ 10 ) Number Trial Sites : 12 Sample Size : 200 consecutive patient 200 historical control , additional 100 ( ) patient bicuspid aortic valve Patient Population : Elderly patient ( ≥65 year age ) severe , symptomatic AS determine Heart Team low surgical risk ( STS score ≤3 % ) .</detailed_description>
	<mesh_term>Constriction , Pathologic</mesh_term>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>1 . Severe , degenerative AS , define : 1. mean aortic valve gradient ≥40 mm Hg OR Vmax ≥4 m/sec AND 2. calculate aortic valve area ≤1.0 cm2 OR aortic valve area index ≤0.6 cm2/m2 2 . Symptomatic AS , define history least one following : 1. dyspnea qualifies New York Heart Association ( NYHA ) class II great 2. angina pectoris 3. cardiac syncope 3 . The Heart Team , include least one cardiothoracic surgeon one interventional cardiologist , deem patient reasonable transfemoral TAVR commercially available bioprosthetic valve 4 . The Heart Team agree patient lowrisk , quantify estimate risk ≤3 % calculated STS score operative mortality 30 day ; AND agree SAVR would appropriate therapy offer . 5 . The Heart Team agree transfemoral TAVR anatomically feasible , base upon multislice CT measurements 6 . Procedure status elective 7 . Expected survival least 24 month For bicuspid cohort : 8 . Aortic Stenosis bicuspid aortic valve 1 . Concomitant disease another heart valve aorta require either transcatheter surgical intervention 2 . Any condition consider contraindication placement bioprosthetic aortic valve ( e.g . patient require mechanical aortic valve ) 3 . Aortic stenosis secondary bicuspid aortic valve ( except bicuspid valve cohort ) 4 . Endstage renal disease require hemodialysis peritoneal dialysis , creatinine clearance &lt; 20 cc/min 5 . Left ventricular ejection fraction &lt; 20 % 6 . Recent ( &lt; 6 month ) history stroke transient ischemic attack 7 . Symptomatic carotid vertebral artery disease , recent ( &lt; 6 week ) surgical endovascular treatment carotid stenosis 8 . Any contraindication oral antiplatelet anticoagulation therapy follow procedure 9 . Severe coronary artery disease unrevascularized 10 . Recent ( &lt; 30 day ) acute myocardial infarction 11 . Patient undergo transfemoral TAVR anatomic reason ( determine supplemental image study ) ; would include inadequate size iliofemoral access vessel aortic annulus size accommodate commercially available valve 12 . Any comorbidity capture STS score would make SAVR high risk , determine cardiothoracic surgeon member heart team ; include : 1. porcelain severely atherosclerotic aorta 2. frailty 3. hostile chest 4 . IMA conduit either cross midline sternum adherent sternum 5. severe pulmonary hypertension ( PA systolic pressure &gt; 2/3 systemic pressure ) 6. severe right ventricular dysfunction 13 . Ongoing sepsis infective endocarditis 14 . Recent ( &lt; 30 day ) ongoing bleed would preclude treatment anticoagulant antiplatelet therapy , include recent gastrointestinal bleeding 15 . Uncontrolled atrial fibrillation ( rest heart rate &gt; 120 beat per minute ) 16 . Severe chronic obstructive pulmonary disease , demonstrate forced expiratory volume ( FEV1 ) &lt; 750 cc 17 . Liver failure Childs class C D 18 . Preprocedure shock , inotropes , mechanical assist device , cardiac arrest</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>